Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18666912 | 0.91 | TMPRSS2 (0.47) | TMPRSS2 | |
| SCHEMBL26295060 | 0.91 | TMPRSS2 (0.43) | TMPRSS2 | |
| SCHEMBL20135819 | 0.90 | TMPRSS2 (0.40) | TMPRSS2 | |
| SCHEMBL25827350 | 0.90 | TMPRSS2 (0.38) | TMPRSS2 | |
| SCHEMBL20078702 | 0.90 | TMPRSS2 (0.33) | TMPRSS2 | |
| SCHEMBL17712236 | 0.90 | TMPRSS2 (0.39) | TMPRSS2 | |
| SCHEMBL17712275 | 0.90 | TMPRSS2 (0.39) | TMPRSS2 | |
| SCHEMBL18666911 | 0.89 | TMPRSS2 (0.43) | TMPRSS2 | |
| SCHEMBL19223101 | 0.89 | TMPRSS2 (0.43) | TMPRSS2 | |
| SCHEMBL26327372 | 0.89 | TMPRSS2 (0.31) | TMPRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207291-A1 | METHODS FOR TREATING POXVIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2024-06-27 | — | — | US | disclosed |
| US-20240024341-A1 | INHALATION FORMULATIONS OF 1`-CYANO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS | GILEAD SCIENCES, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230364121-A1 | NIRAN INTERFERING DRUGS FOR SARS-COV-2 MUTANT THERAPY | Atea Pharmaceuticals, Inc. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230346812-A1 | METHODS FOR TREATING SARS COV-2 INFECTIONS | GILEAD SCIENCES, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230295172-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230287029-A1 | ANTIVIRAL PRODRUGS, PHARMACEUTICAL FORMULATIONS, AND METHODS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-09-14 | — | — | US | disclosed |
| US-11738038-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230233587-A1 | REMDESIVIR TREATMENT METHODS | GILEAD SCIENCES, INC. | 2023-07-27 | — | — | US | disclosed |
| US-11701372-B2 | Inhalation formulations of 1'-cyano substituted carba-nucleoside analogs | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230219993-A1 | ANTIVIRAL APPLICATION OF NUCLEOSIDE ANALOG OR COMBINATION FORMULATION CONTAINING NUCLEOSIDE ANALOG | VIGONVITA LIFE SCIENCES CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
| US-20200197422-A1 | METHODS FOR THE PREPARATION OF RIBOSIDES | GILEAD SCIENCES, INC. | 2020-06-25 | — | — | US | disclosed |
| US-10675296-B2 | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections | GILEAD SCIENCES, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20190275063-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2019-09-12 | — | — | US | disclosed |
| US-20190255085-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2019-08-22 | — | — | US | disclosed |
| US-10251904-B2 | Methods for treating arenaviridae and coronaviridae virus infections | GILEAD SCIENCES, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-10251898-B2 | Methods for treating Filoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-20190083525-A1 | COMPOSITIONS COMPRISING AN RNA POLYMERASE INHIBITOR AND CYCLODEXTRIN FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2019-03-21 | — | — | US | disclosed |
| US-9949994-B2 | Methods for treating Filoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9724360-B2 | Methods for treating Filoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20170071964-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2017-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (18 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364121-A1 | NIRAN INTERFERING DRUGS FOR SARS-COV-2 MUTANT THERAPY | NSUN2, ACE2, PNP | TMPRSS2 12/4885 |
| US-10251904-B2 | Methods for treating arenaviridae and coronaviridae virus infections | ACE, PNP, ACE2 | TMPRSS2 12/4885 |
| US-20190275063-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | PNP, PRPF4, RPIA | TMPRSS2 1951/4885 |
| US-20230233587-A1 | REMDESIVIR TREATMENT METHODS | EIF2AK2, MTAP, ACE | TMPRSS2 259/4885 |
| US-20190255085-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | ACE, PNP, ACE2 | TMPRSS2 12/4885 |
| US-11738038-B2 | Highly active compounds against COVID-19 | PNP, ACE2, MTAP | TMPRSS2 97/4885 |
| US-10251898-B2 | Methods for treating Filoviridae virus infections | PNP, PRPF4, RPIA | TMPRSS2 1951/4885 |
| US-20170071964-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | ACE, PNP, ACE2 | TMPRSS2 12/4885 |
| US-20230219993-A1 | ANTIVIRAL APPLICATION OF NUCLEOSIDE ANALOG OR COMBINATION FORMULATION CONTAINING NUCLEOSIDE ANALOG | PNP, TYMP, PIGS | TMPRSS2 145/4885 |
| US-20200197422-A1 | METHODS FOR THE PREPARATION OF RIBOSIDES | PRPS1, PRPF4, PRPF31 | TMPRSS2 3100/4885 |
| US-10675296-B2 | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections | CTDSP1, RNGTT, POLRMT | TMPRSS2 2155/4885 |
| US-20240024341-A1 | INHALATION FORMULATIONS OF 1`-CYANO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS | SLC29A1, SLC28A1, RNMT | TMPRSS2 4176/4885 |
| US-20230346812-A1 | METHODS FOR TREATING SARS COV-2 INFECTIONS | ACE2, ACE, PNP | TMPRSS2 6/4885 |
| US-20190083525-A1 | COMPOSITIONS COMPRISING AN RNA POLYMERASE INHIBITOR AND CYCLODEXTRIN FOR TREATING VIRAL INFECTIONS | CTDSP1, RNGTT, POLRMT | TMPRSS2 2155/4885 |
| US-20230287029-A1 | ANTIVIRAL PRODRUGS, PHARMACEUTICAL FORMULATIONS, AND METHODS | MTAP, SARS1, RNGTT | TMPRSS2 181/4885 |
| US-20230295172-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | TMPRSS2 112/4885 |
| US-11701372-B2 | Inhalation formulations of 1'-cyano substituted carba-nucleoside analogs | SLC29A1, SLC28A1, SLC29A2 | TMPRSS2 4231/4885 |
| US-20240207291-A1 | METHODS FOR TREATING POXVIRUS INFECTIONS | VAC14, SDHB, XDH | TMPRSS2 2934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.